CLR 131 not checked

Cellectar Biosciences, Inc. · Iopofosine I 131 single · Iopofosine I 131 multiple

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
5 active
6 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA”In the company’s words, NCT05610891 on ClinicalTrials.gov
Tested for
Waldenstrom Macroglobulinemia (2 trials), Waldenstrom Macroglobulinaemia, Waldenstrom's Macroglobulinaemia Refractory, Waldenstrom Macroglobulinemia With Nodal Disease, Waldenstrom's Macroglobulinemia Recurrent, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and 15 more
Main trialPhase 3
“The goal of this clinical trial is to evaluate whether iopofosine I 131 is more effective than the combination Rituximab-Cyclophosphamide-Dexamethasone (R-CD). The main question the study aims to answer is: • Does iopofosine I 131 work better than R-CD when looking at the length of time during and after the treatment that a patient lives with WM but it does not get worse. Participants will: * Be randomly assigned to received either iopofosine I 131 or R-CD. * If assigned to iopofosine I 131, have it administered via infusion 2 times each cycle for a total of 2 cycles (each cycle is about 3…”In the company’s words, NCT07766421 on ClinicalTrials.gov
Other names
Iopofosine I 131 single · Iopofosine I 131 multiple · Iopofosine I 131 fractionated · Iopofosine I · iopofosine I 131 · I-131-CLR1404 · 131I-CLR1404

Other drugs for Waldenstrom Macroglobulinemia

All 25 drugs for Waldenstrom Macroglobulinemia

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Jan 2032 Evaluation of Iopofosine I 131 vs. R-CD in WM Patients
Phase 2Active, not recruiting 22 Jun 2026 Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Phase 1Active, not recruiting 30 Jun 2027 Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Phase 1Active, not recruiting 30 Jun 2027 Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Phase 1Recruiting Feb 2028 Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Phase 1Completed 9 Dec 2020 Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CLR 131

Following is part of Solo: you see every change to CLR 131 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in